Table 3. CD19-targeted trials for the treatment of chronic lymphocytic leukemia.

Institution/CAR	Conditioning and dosing	Patient population	Clinical responses	CAR T-cell persistence	Ref.
MSKCC SJ25-28z	None, n = 3 1 dose Cy, n = 4 1 dose bendamustine, n = 2 0.4-3.0 × 107 CAR T cells/kg	n = 9, R/R CLL 44–66 y/o	No preTx: 3/3 PD Cy preTx: – D bendamustine preTx: 1 MRD CR and 1 PR no Scrs	Persistence out to 30 days detected by qPCR	[19, 20]
UPenn CHOP FMC63-BBz	Pre Tx 3-5 days pre 5 × 107-5 × 108 CAR T cells/kg	n = 26, R/R CLL Median 62 y/o	22% CR, 17% PR 43% NR 3 relapse (incl. CD19) 14/26 CRS, n = 3 sCRS (intervention)	Persistence by flow cytometry Time unknown	[15–18]
NCI FM63-28z	2 doses Cy 60 mg/kg, 5 doses Flu 25 mg/m2 0.3–2.8 × 107 CAR T cells/kg +IL-2 (720000 IU/kg/8 h)	n = 4 R/R CLL, aged 54 – 61 y/o	n = 1 CR, n = 2 PR, n = 1 SD IL-2 toxicity and CRs	Persistence up to 181 days by qPCR	[21]
	1 dose Cy 60 –120 mg/kg, 5 doses Flu 25 mg/m2 1–5 × 106 CAR T cells/kg	n = 4, R/R CLL Aged 48 = 68 y/o	3/4 classically defined CR, CR > grade 3, n = 4	Persistence up to 65 days by qPCR	[22]
	0.4-2.4 × 106 CAR T cells/kg Post allo-SCT, no preTx	n = 4, R/R CLL Aged 44–66 y/o	n = 1 CR (9 mo), n = 1 PR, n = 2 PD No GVHD exacerbation Tumor lysis syndrome	Peristence to 30 days detected by qPCR	[23]

Allo-SCT: Allogeneic stem cell transplant; CLL: Chronic lymphocytic leukemia; CAR: Chimeric antigen receptor; CR: Complete response; CRS: Cytokine release syndrome; Cy: Cyclophosphamide; Flu: Fludarabine; GVHD: Graft versus host disease; incl.: Including; Mo: Months; MRD: Minimal residual disease; MSKCC: Memorial Sloan Kettering Cancer Center; NCI: National Cancer Center; NR: No response; PR: Partial response; qPCR: Quantitative PCR; R/R: Relapsed refractory; sCRS: Severe cytokine release syndrome; SD: Stable disease; Tx: Treatment; UPenn: The University of Pennsylvania; y/o: Years old.